Welcome to our dedicated page for Silence Therapeutics Plc SEC filings (Ticker: SLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D expenses hidden in footnotes, milestone payments buried in 8-K exhibits, and pages of RNAi jargon鈥擲ilence Therapeutics鈥� SEC filings can feel like a clinical protocol rather than an investor document. If you have ever wondered, 鈥淗ow do I decode a Silence Therapeutics annual report 10-K simplified?鈥� or 鈥淲here are Silence Therapeutics insider trading Form 4 transactions listed?鈥�, you are not alone.
Stock Titan solves that problem by pairing every submission鈥�10-K, 10-Q, 8-K, Form 4, and the DEF 14A proxy statement鈥攚ith AI-powered summaries that explain complex RNA interference science in plain English. Our engine instantly highlights trial milestones, cash runway metrics, and collaboration payments, letting you move from question to answer: 鈥渦nderstanding Silence Therapeutics SEC documents with AI鈥�, 鈥淪ilence Therapeutics executive stock transactions Form 4鈥�, or 鈥淪ilence Therapeutics 8-K material events explained鈥�. AG真人官方-time alerts ensure you see Silence Therapeutics Form 4 insider transactions real-time, track each Silence Therapeutics quarterly earnings report 10-Q filing, and review every Silence Therapeutics proxy statement executive compensation table the moment it hits EDGAR.
Whether you need a quick 鈥淪ilence Therapeutics earnings report filing analysis鈥� before a conference call or want to monitor 鈥淪ilence Therapeutics insider trading Form 4 transactions鈥� ahead of pivotal trial data, our comprehensive coverage and expert commentary keep critical disclosures at your fingertips. Make informed decisions faster with streamlined access to every Silence Therapeutics SEC filing鈥攅xplained simply, updated instantly, and organized for biotech investors who value clarity over clutter.
Silence Therapeutics plc (SLN) 鈥� Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).
- 31 Jul 2025: 14,342 ADS at $6.18
- 1 Aug 2025: 4,034 ADS at $6.14
The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.
The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.
Silence Therapeutics plc (SLN) 鈥� Form 4 insider buying
10% owner Richard Ian Griffiths, via Cream Capital Ltd., disclosed open-market purchases on 21-22 Jul 2025 of 25,345 American Depositary Shares (ADS) at $6.04 and $6.09. Each ADS converts into three ordinary shares, increasing his indirect holding by roughly 76,035 ordinary shares.
Post-trade, Griffiths鈥� beneficial position totals 鈮�11.78 million ADS-equivalent shares. No sales were reported. Continued accumulation by a 10% holder generally signals confidence in the company鈥檚 outlook and may support sentiment toward SLN shares.
Silence Therapeutics (NASDAQ:SLN) filed a routine Form 8-K disclosing voting results from its 26 June 2025 Annual General Meeting. Shareholders approved all 13 resolutions, including the re-appointment of directors David Lemus, Tim McInerney, Iain Ross and Craig Tooman; an annual non-binding say-on-pay vote; ratification of PricewaterhouseCoopers LLP as both U.S. and U.K. auditors; adoption of the 2024 U.K. statutory accounts; and replacement of the company鈥檚 articles of association. Support levels exceeded 90% for most items (e.g., Craig Tooman re-elected with 78.23 M votes for vs. 28.4 k against). The board will continue to seek shareholder input on executive compensation annually. No other material business, strategic changes or financial disclosures were announced.
Silence Therapeutics Plc (SLN) 鈥� Schedule 13D/A Amendment No. 9
The filing discloses the updated beneficial ownership of long-time shareholder Richard Ian Griffiths and several Jersey-based entities he controls. After recent open-market activity and an increase in the company鈥檚 share capital, Mr. Griffiths now reports 34,543,302 ordinary shares (held directly and through seven entities), representing 24.4 % of SLN鈥檚 141,690,849 outstanding shares. Voting and dispositive power for all shares is held solely by Mr. Griffiths.
Recent transactions: Between 8 May 2025 and 24 Jun 2025, Mr. Griffiths purchased an additional 543,581 ADSs on the open market for a combined cash consideration of US $2.7 million; each ADS equals three ordinary shares. These purchases were funded with personal or affiliated-company cash.
Entity breakdown:
- Ora Capital Ltd 鈥� 19,221,525 ordinary shares (13.6 %)
- Sarossa Plc 鈥� 1,815,522 shares
- Cream Capital Ltd 鈥� 3,967,896 shares
- Blake Holdings Ltd 鈥� 300,000 shares
- Ora Ventures Ltd 鈥� 360,000 shares
- Pinkey鈥檚 Ltd 鈥� 190,500 shares
- Direct holding 鈥� 8,687,859 shares
The amendment notes that the percentage ownership has changed because of both the incremental ADS purchases and dilution stemming from a recent increase in the Issuer鈥檚 share capital. No new contracts, voting agreements or other material relationships were reported, and a standard joint-filing agreement is included as an exhibit.
FAQ
What is the current stock price of Silence Therapeutics Plc (SLN)?
What is the market cap of Silence Therapeutics Plc (SLN)?
